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Summary
Background The value of screen detection and treatment of ductal carcinoma in situ (DCIS) is a matter of controversy. 
At present, the extent to which the diagnosis and treatment of DCIS could prevent the occurrence of invasive breast 
cancer in the future is not clear. We sought to estimate the association between detection of DCIS at screening and 
invasive interval cancers subsequent to the relevant screen.
Methods We obtained aggregate data for screen-detected cancers from 84 local screening units within 11 regional 
Quality Assurance Reference Centres in England, Wales, and Northern Ireland from the National Health Service 
Breast Screening Programme. Data for DCIS diagnoses were obtained for women aged 50–64 years who were 
invited to and attended mammographic breast screening from April 1, 2003, to March 31, 2007 (4 screening years). 
Patient-level data for interval cancer arising in the 36 months after each of these were analysed by Poisson regression 
with invasive interval cancer screen detection rate as the outcome variable; DCIS detection frequencies were ﬁ tted 
ﬁ rst as a continuous and then as a categorical variable. We repeated this analysis after adjustment with both small 
size and high-grade invasive screen-detected cancers.
Findings We analysed data for 5 243 658 women and on interval cancers occurring in the 36 months after the relevant 
screen. The average frequency of DCIS detected at screening was 1·60 per 1000 women screened (median 1·50 [unit 
range 0·54–3·56] per 1000 women). There was a signiﬁ cant negative association of screen-detected DCIS cases with 
the rate of invasive interval cancers (Poisson regression coeﬃ  cient –0·084 [95% CI –0·13 to –0·03]; p=0·002). 90% 
of units had a DCIS detection frequency within the range of 1·00 to 2·22 per 1000 women; in these units, for every 
three screen-detected cases of DCIS, there was one fewer invasive interval cancer in the next 3 years. This association 
remained after adjustment for numbers of small screen-detected invasive cancers and for numbers of grade 3 
invasive screen-detected cancers.
Interpretation The association between screen-detected DCIS and subsequent invasive interval cancers suggests that 
detection and treatment of DCIS is worthwhile in prevention of future invasive disease.
Funding UK Department of Health Policy Research Programme and NHS Cancer Screening Programmes.
Copyright © Duﬀ y et al. Open Access article distributed under the terms of CC BY.
Introduction
The beneﬁ t-to-harm balance of screen detection and 
subsequent treatment of ductal carcinoma in situ of 
the breast (DCIS) has been a matter of debate.1–3 DCIS 
was rare in the era before screening, and a major 
question is the extent to which diagnosis and treatment 
of DCIS could prevent the occurrence of invasive 
breast cancer in the future.4 In two randomised trials of 
screening, an excess of DCIS in the study groups was 
almost entirely balanced by a corresponding deﬁ cit in 
invasive disease.5 Further, in a trial of treatment of 
DCIS, those cases who had only received wide local 
excision had a 10-year rate of subsequent breast cancer 
events of more than 30%, suggesting a serious potential 
of DCIS for progression.6 The fact remains, however, 
that for any individual DCIS case that is treated, it 
cannot be known for certain what would have happened 
if the treatment had not taken place.6 However, with 
suﬃ  cient aggregate data, it might be possible to assess 
the eﬀ ect of screen detection of DCIS on the subsequent 
incidence of invasive cancer in a population subject to 
screening.
In this study, we sought to estimate the association 
between detection of DCIS at screening and invasive 
interval cancers subsequent to the relevant screen at unit 
level using data from the UK National Health Service 
Breast Screening Programme (NHSBSP).
Methods
Study population and design
The NHSBSP oﬀ ers mammographic screening every 
3 years to roughly 2 million women older than 50 years per 
year in the UK as a whole, and routinely invites women 
aged 50–70 years.7
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We obtained aggregate data for screen-detected 
cancers from 84 local screening units within 11 regional 
Quality Assurance Reference Centres in England, 
Wales, and Northern Ireland from the NHSBSP via the 
NHS Information Centre (now the Health and Social 
Care Information Centre [HSCIC]) and its counterparts 
in Northern Ireland and Wales. Data for breast cancer 
diagnoses, including DCIS, were obtained for women 
aged 50–64 years (age range of the programme at its 
inception) who were invited to and attended 
mammographic breast screening from April 1, 2003, to 
March 31, 2007 (4 screening years). Patient-level data for 
interval cancer were obtained from the regional 
screening Quality Assurance Reference Centres, who in 
turn received notiﬁ cations of subsequent interval 
cancers arising in the 36 months following screening 
from their regional cancer registries, for the number of 
subsequent interval cancers arising in the 36 months 
after each of these screening years. Interval cancer data 
for Scotland was unavailable for all but one of the 
screening years so this region was excluded from the 
primary analysis. Where regional boundaries changed 
during the period under scrutiny, conﬁ gurations of 
regions and responsibilities for units were taken to be 
those that existed in screening year 2006–07.
Procedures
From the aggregate data, we were able to ascertain the 
proportion of women diagnosed with DCIS and 
invasive tumours. When available we obtained DCIS 
grade and invasive tumour size and grade; DCIS 
tumours are graded as low, intermediate, and high, 
with low and intermediate grades grouped together. 
Usually, DCIS is treated with complete local excision 
followed by radiotherapy; however, the NHSBSP data 
are recorded mainly to monitor performance and thus 
do not contain information regarding subsequent 
treatment of patients with screen-detected cancer. As in 
a previous report,8 interval cancers were deﬁ ned as 
cancers diagnosed symptomatically in women within 
36 months of their last screen (the maximum speciﬁ ed 
interval in the NHSBSP). For this analysis, we included 
ﬁ rst and second primary, bilateral, and recurrent 
invasive interval cancers, but excluded contralateral 
interval cancers to ensure the outcome variable 
consisted of new primary breast cancers and because it 
is unlikely that the removal of a DCIS in one breast 
could prevent an invasive tumour in the contralateral 
breast.
Statistical analysis
For our primary analysis, we estimated the association 
between the frequency of DCIS cases diagnosed at 
screening and subsequent invasive interval cancer 
incidence using Poisson regression,9 with the following 
regression equation:
where i represents invasive interval cancers in the 
individual screening unit following screening in an 
individual year, s is the total number screened in that 
unit and year, D is the number of screen-detected DCIS 
cases in that unit and year, and a and b are the 
coeﬃ  cients to be estimated. In addition, we tabulated 
the incidence of invasive interval cancers by DCIS 
detection frequency in four categories (<1 per 1000; 
1–<1·5 per 1000; 1·5–<2 per 1000; and ≥2 per 1000), and 
ﬁ tted the corresponding Poisson regression model. 
This allowed us to estimate the absolute deﬁ cit or 
increase in terms of the number of invasive interval 
cancers pertaining to diﬀ erent frequencies of DCIS, 
without assuming a parametric form for the 
relationship. In addition, we ﬁ tted the Poisson 
regression models adjusted for the number of screen-
detected grade 3 and small (<15 mm in diameter) 
Research in context
Evidence before this study
The value of screen detection and treatment of ductal carcinoma 
in situ (DCIS) is a matter of controversy. It is not clear the extent 
to which diagnosis and treatment of DCIS could prevent the 
occurrence of invasive breast cancer in the future.
We searched PubMed with the search terms “ductal carcinoma in 
situ” and “screening” and “breast” and “invasive” and “incidence” 
for publications reporting on studies of any design investigating 
the eﬀ ect of screen detection of DCIS on incidence of subsequent 
invasive cancer, published in any language between Jan 1, 1990, 
and  July 31, 2015. We identiﬁ ed a paper reporting on the eﬀ ect 
of DCIS detection on invasive disease incidence in two 
randomised trials, but none from service screening programmes. 
The search was repeated with “ductal carcinoma in situ” replaced 
by “DCIS”, and no further relevant publications were identiﬁ ed.
Added value of this study
Using data from the UK NHS Breast Screening Programme, we 
estimated the eﬀ ect of screen-detected DCIS on invasive interval 
cancers subsequent to the relevant screen at unit level. We found 
a negative association between detection of DCIS at screening 
and invasive interval cancers.
Implications of all the available evidence
This suggests that the policy of detection and treatment of 
DCIS in breast cancer screening can prevent subsequent 
invasive disease.
log   i
  s
= a+b × log   D  s
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invasive cancers, because there is evidence that high 
numbers of small invasive tumours detected at 
screening are associated with lower interval cancer 
incidence.10 Signiﬁ cance was assessed with Wald tests, 
with p values of less than 0·05 being regarded as 
signiﬁ cant. Because the average interval between 
screening rounds varies from unit to unit (although 
most units achieve an average interval of less than 
36 months), we also reanalysed the data with only the 
interval cancers diagnosed within the ﬁ rst 24 months 
following a negative screen, since no unit operated an 
interval shorter than this, and because 24 months is the 
standard screening interval in many other countries.2,10 
We also repeated the analysis to include the data 
available from Scotland for screening year 2003–04. 
Data were analysed with Stata (version 12).
Role of the funding source
The funders had no role in the study design; collection, 
analysis, or interpretation of the data; or the writing of 
the report. SWD, AD, DM, JO, and DP had full access to 
all of the raw data. The corresponding author had the 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
We obtained aggregated screening data for 
5 243 658 women screened between April 1, 2003, and 
March 31, 2007. The number of women screened by 
each screening unit each year is shown in the appendix. 
One unit in the South West region only began screening 
in 2004–05 and thus we have data covering three 
screening years for this unit. Another unit in the East 
of England suspended screening between November, 
2004, and January, 2006. Subsequently, only 550 women 
were screened during screening year 2005–06. All 
analyses were done both including and excluding these 
women; the results were identical so we present the 
results excluding data of these 550 women from the 
analysis.
The average number of women screened annually per 
unit was 15 700 (unit range 3835–40 146). Table 1 shows 
the incidence of screen-detected DCIS and screen-
detected invasive cancers for each screening year, and 
the incidence of subsequent invasive interval cancers. 
The average frequency of DCIS detected at screening 
was 1·60 per 1000 women screened (median 1·50 [unit 
range 0·54–3·56] per 1000). Among DCIS cases that 
were graded, there was a higher proportion of low-grade 
DCIS in units with a detection frequency higher than 
1·5 per 1000 than in those units with a detection 
frequency of 1·5 per 1000 or less (1866 [40%] of 4663 vs 
967 [38%] of 2569; p=0·008). The average frequency of 
screen-detected invasive cancers was 5·53 per 
1000 women screened (unit range 0–7·99). The 
subsequent average detection frequency of invasive 
interval cancers was 2·90 per 1000 screened (unit range 
0·74–5·60 per 1000).
The primary analysis to estimate the association 
between screen-detected DCIS incidence and 
subsequent invasive interval cancer incidence resulted 
in a Poisson regression coeﬃ  cient of –0·084 (95% CI 
–0·13 to –0·03), a signiﬁ cant negative association 
(p=0·002). The Poisson regression coeﬃ  cient is 
equivalent to the logarithm of the relative risk (RR), 
thus a coeﬃ  cient of –0·084 indicates a reduction in risk 
of an invasive interval cancer per unit increase in the 
logarithm of the detection frequency of DCIS (RR 0·92 
[95% CI 0·87–0·98]). The ﬁ tted incidence of invasive 
interval cancers per 1000 from the Poisson regression 
Total number 
screened
DCIS cases 
detected at 
screening
 Screen-detected DCIS 
cases per 1000  women 
screened (unit range)
Screen-detected DCIS 
cases with grading 
information (%)
High grade 
screen-
detected DCIS
Invasive cases 
detected at 
screening
Invasive screen-
detected cases per 
1000 women 
screened (unit range)
Invasive 
interval 
cancers
Invasive interval 
cancers per 
1000 women screened 
(unit range)
2003–04 1 279 007 2003 1·57 (0·73–2·85) 1671 (83%) 997 6952 5·44 (0–7·61) 3789 2·96 (1·00–4·96)
2004–05 1 286 244 2033 1·58 (0·67–3·56) 1708 (84%) 1036 7194 5·59 (3·74–7·99) 3688 2·87 (0·74–4·05)
2005–06 1 340 046 2144 1·60 (0·54–2·85) 1842 (86%) 1119 7504 5·60 (3·85–7·64) 4000 2·98 (1·27–5·60)
2006–07 1 338 361 2205 1·65 (0·59–3·22) 1956 (89%) 1213 7364 5·50 (3·77–7·77) 3737 2·79 (1·25–4·61)
DCIS=ductal carcinoma in situ.
Table 1: DCIS and invasive cancer detection frequency, and subsequent invasive interval cancer frequency by year of screening
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Figure: Fitted invasive interval cancer incidence from Poisson regression as a 
function of DCIS detection frequency at the previous screen
DCIS=ductal carcinoma in situ.
See Online for appendix
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plotted against the frequency of screen-detected DCIS 
per 1000 is shown in the ﬁ gure. For up to around 1·5 per 
1000 women screened, there are estimated two fewer 
invasive interval cancer cases for every three DCIS 
cases; from 1·5 to 2·5 per 1000, around one invasive 
interval cancer case is estimated to be avoided per ﬁ ve 
DCIS cases. When the analyses were adjusted for 
grade 3 invasive cancers or small invasive cancers 
(<15 mm) the results remained unchanged from the 
primary analysis (table 2). We repeated this analysis 
after restricting interval cancers to those diagnosed 
within 24 months after a negative screen and after 
including the 1 year of data available from Scotland. 
Results of the Poisson regressions in relation to the 
magnitude and signiﬁ cance of the Poisson regression 
coeﬃ  cient were similar to that of the primary analysis 
(table 2).
To estimate the absolute change in invasive interval 
cancers corresponding to diﬀ erent detected frequencies 
of DCIS without assuming a speciﬁ c mathematical 
form of the association, we ﬁ tted the model with DCIS 
detection frequencies as a categorical variable (table 3). 
These data suggest that at a DCIS detection frequency 
of 1–1·5 per 1000, for two DCIS cases detected at 
screening, one invasive cancer in the interval 
immediately following the screen was avoided 
(a diﬀ erence of 3·15–2·94=0·21 per 1000 invasive 
interval cancers compared with 1·27–0·85=0·42 per 
1000 screen-detected DCIS). For units with DCIS 
detection rates above 1·5 per 1000, there was a reduction 
of one invasive interval cancer per six DCIS cases 
detected. 90% of units had a DCIS frequ within the 
range of 1·00 to 2·22 per 1000; within this range, 
roughly one fewer invasive interval cancer was noted 
per three screen-detected DCIS cases (ﬁ gure).
Discussion
Using data from the UK NHSBSP we identiﬁ ed a 
signiﬁ cant negative association between the number of 
DCIS cases detected at screening and the number of 
invasive cancers occurring in the subsequent 3-year 
interval. To our knowledge, this is the ﬁ rst study to 
explicitly investigate the association between screen 
detection of DCIS and subsequent incidence of invasive 
breast cancer. Previous research has suggested that the 
frequency of detection of small invasive cancers might be 
negatively correlated with subsequent interval cancer 
incidence10 and increased detection of DCIS has been 
associated with similarly increased detection of grade 3 
invasive cancers.11 Our results were unchanged when we 
adjusted for the detection of small invasive cancers and 
when we adjusted for the detection of grade 3 invasive 
cancers.
Our results suggest that at low levels of screen-detected 
DCIS, up to 1·5 per 1000, a reduction of one invasive 
interval cancer is observed per 1·5–3 DCIS cases 
detected, and that at higher levels of detection, one less 
invasive interval cancer is observed per ﬁ ve or six screen-
detected DCIS cases. One possible interpretation is that 
there might be diminishing returns with more 
aggressive diagnostic approaches to microcalciﬁ cations, 
resulting in high detection frequencies of DCIS. On the 
other hand, it could be that detection of DCIS above two 
per 1000 prevents invasive cancers more than 3 years in 
the future, and that our study of the single interval after 
screen detection is too short to observe this. We noted 
that the units with increased detection of DCIS overall 
had increased proportions of low-grade DCIS, which 
might be expected to progress to invasive disease over a 
time period longer than 3 years. For units with DCIS 
screen-detection frequencies that fall within the 90% 
range for all units, on average one invasive interval 
cancer would be avoided per three additional DCIS cases 
detected.
Our results are ecological, based on screening unit 
level data. This means, for example, that we cannot link 
DCIS cases detected at screening with invasive interval 
cancers at the individual level. We have also made no 
adjustment for age, although we would not anticipate 
major variation among units within the relatively 
narrow window of 50–64 years. Both DCIS screen-
detection frequency and invasive interval cancer 
frequency would be expected to increase slightly with 
age.7,8 Our ﬁ ndings cannot give deﬁ nitive proof of the 
progressive potential or otherwise of individual DCIS 
Average DCIS 
detection per 1000
Invasive interval 
cancers/total screened
Invasive interval 
cancers per 1000
RR (95% CI)
<1 per 1000 0·85 1236/392 982 3·15 1·0
1–<1·5 per 1000 1·27 6069/2 063 030 2·94 0·94 (0·88–0·99)
1·5–<2·0 per 1000 1·72 4844/1 686 588 2·87 0·91 (0·86–0·97)
≥2 per 1000 2·25 3065/1 101 058 2·78 0·89 (0·83–0·95)
DCIS=ductal carcinoma in situ. RR=relative risk.
 Table 3: Association of categorised DCIS detection frequencies at screening with subsequent invasive 
interval cancer incidence
Poisson regression coeﬃ  cient 
(95% CI)
p value
Adjustment for small (<15 mm) invasive tumours
Frequency of screen-detected DCIS –0·080 (–0·13 to –0·03) 0·003
Small screen-detected tumours –0·0003 (–0·001 to 0·0004) 0·38
Adjustment for screen-detected grade 3 invasive tumours
Frequency of screen-detected DCIS –0·089 (–0·14 to –0·03) 0·001
Grade 3 screen-detected tumours 0·0003 (–0·0003 to 0·001) 0·35
Restriction to invasive interval cancers diagnosed within 24 months
Frequency of screen-detected DCIS –0·089 (–0·16 to –0·016) 0·016
Repeat of primary analysis to include the 2003–04 data from Scotland
Frequency of screen-detected DCIS –0·086 (–0·14 to –0·033) 0·001
DCIS=ductal carcinoma in situ.
Table 2: Results of secondary analyses of association of DCIS detection frequencies with subsequent 
invasive interval cancer incidence
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Midlands. BC was responsible for screening and interval cancer results 
for the East of England. TR was responsible for screening and interval 
cancer results for London. SSc was responsible for screening and interval 
cancer results for the North East and Yorkshire and the Humber. KG was 
responsible for screening and interval cancer results for the North West. 
CH was responsible for screening and interval cancer results for Northern 
Ireland. X-HL was responsible for screening and interval cancer results 
for South Central. MR was responsible for screening and interval cancer 
results for the South East Coast. FJ was responsible for screening and 
interval cancer results for the South West. GS was responsible for 
screening and interval cancer results for Wales. OK was responsible for 
screening and interval cancer results for the West Midlands. SSe 
contributed to programme management. JP directed the screening 
programme.
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